Search Page

1

Cite

Share

Management of fracture risk in patients with diabetes-Chinese Expert Consensus.

Liu JM, Zhu DL, Mu YM, Xia WB; Chinese Society of Osteoporosis and Bone Mineral Research, the Chinese Society of Endocrinology, Chinese Diabetes Society, Chinese Medical Association; Chinese Endocrinologist Association, Chinese Medical Doctor Association. Liu JM, et al. J Diabetes. 2019 Nov;11(11):906-919. doi: 10.1111/1753-0407.12962. Epub 2019 Aug 12. J Diabetes. 2019. PMID: 31219236 No abstract available.

Cite

Share

2

Cite

Share

Current status, problems, and perspectives of non-alcoholic fatty liver disease research.

Tanaka N, Kimura T, Fujimori N, Nagaya T, Komatsu M, Tanaka E. Tanaka N, et al. World J Gastroenterol. 2019 Jan 14;25(2):163-177. doi: 10.3748/wjg.v25.i2.163. World J Gastroenterol. 2019. PMID: 30670907 Free PMC article. Review.

Cite

Share

3

Cite

Share

Nonalcoholic steatohepatitis: the role of peroxisome proliferator-activated receptors.

Francque S, Szabo G, Abdelmalek MF, Byrne CD, Cusi K, Dufour JF, Roden M, Sacks F, Tacke F. Francque S, et al. Nat Rev Gastroenterol Hepatol. 2021 Jan;18(1):24-39. doi: 10.1038/s41575-020-00366-5. Epub 2020 Oct 22. Nat Rev Gastroenterol Hepatol. 2021. PMID: 33093663 Review.

Cite

Share

4

Cite

Share

Peroxisome Proliferator-Activated Receptors and Their Novel Ligands as Candidates for the Treatment of Non-Alcoholic Fatty Liver Disease.

Fougerat A, Montagner A, Loiseau N, Guillou H, Wahli W. Fougerat A, et al. Cells. 2020 Jul 8;9(7):1638. doi: 10.3390/cells9071638. Cells. 2020. PMID: 32650421 Free PMC article. Review.

Cite

Share

5

Cite

Share

Emerging drugs for the treatment of non-alcoholic steatohepatitis: a focused review of farnesoid X receptor agonists.

Shah RA, Alkhouri N, Kowdley KV. Shah RA, et al. Expert Opin Emerg Drugs. 2020 Sep;25(3):251-260. doi: 10.1080/14728214.2020.1796968. Epub 2020 Aug 12. Expert Opin Emerg Drugs. 2020. PMID: 32686578 Review.

Cite

Share

6

Cite

Share

Pioglitazone Decreased Bone Mineral Density and Bone-Specific Alkaline Phosphatase: A Systematic Review and Meta-analysis.

Sun T, Yan T, Zhao Y, Chen A. Sun T, et al. Am J Ther. 2020 Nov/Dec;27(6):e701-e704. doi: 10.1097/MJT.0000000000001116. Am J Ther. 2020. PMID: 31833873 No abstract available.

Cite

Share

7

Cite

Share

Pioglitazone for prevention or delay of type 2 diabetes mellitus and its associated complications in people at risk for the development of type 2 diabetes mellitus.

Ipsen EØ, Madsen KS, Chi Y, Pedersen-Bjergaard U, Richter B, Metzendorf MI, Hemmingsen B. Ipsen EØ, et al. Cochrane Database Syst Rev. 2020 Nov 19;11(11):CD013516. doi: 10.1002/14651858.CD013516.pub2. Cochrane Database Syst Rev. 2020. PMID: 33210751 Free PMC article.

Cite

Share

8

Cite

Share

The Asian Pacific Association for the Study of the Liver clinical practice guidelines for the diagnosis and management of metabolic associated fatty liver disease.

Eslam M, Sarin SK, Wong VW, Fan JG, Kawaguchi T, Ahn SH, Zheng MH, Shiha G, Yilmaz Y, Gani R, Alam S, Dan YY, Kao JH, Hamid S, Cua IH, Chan WK, Payawal D, Tan SS, Tanwandee T, Adams LA, Kumar M, Omata M, George J. Eslam M, et al. Hepatol Int. 2020 Dec;14(6):889-919. doi: 10.1007/s12072-020-10094-2. Epub 2020 Oct 1. Hepatol Int. 2020. PMID: 33006093

Cite

Share

9

Cite

Share

PPAR-Targeted Therapies in the Treatment of Non-Alcoholic Fatty Liver Disease in Diabetic Patients.

Lange NF, Graf V, Caussy C, Dufour JF. Lange NF, et al. Int J Mol Sci. 2022 Apr 13;23(8):4305. doi: 10.3390/ijms23084305. Int J Mol Sci. 2022. PMID: 35457120 Free PMC article. Review.

Cite

Share

10

Cite

Share

Obeticholic acid for the treatment of nonalcoholic steatohepatitis.

Shah RA, Kowdley KV. Shah RA, et al. Expert Rev Gastroenterol Hepatol. 2020 May;14(5):311-321. doi: 10.1080/17474124.2020.1748498. Epub 2020 May 12. Expert Rev Gastroenterol Hepatol. 2020. PMID: 32241197

Cite

Share